Si Houn Hahn
Clinical Biochemical Genetics · Seattle, WANPI 1538109558
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,125 of the $10,476 with a category attached, or 96.6%. AstraZeneca accounts for 99.3% of it on its own, with 2 other manufacturers making up the rest. 2022 is the largest year on record at $10,125, more than ten times the $321 reported in 2019.
Across 7 payments — averaging $1496.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Sanofi$45
- Ultragenyx Pharmaceutical Inc.$30
Across 135 payments — averaging $10,077 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$477K
- Sanofi$458K
- Shire North American Group Inc$218K
- Ultragenyx Pharmaceutical Inc.$207K
What the payments were for
- Consulting fees$10,12597%
- Food & beverage$3213%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $10,401 |
| Sanofi | 1 | $45 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
How this compares
Too few clinical biochemical genetics providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Other clinical biochemical genetics in Seattle
- Gerald NepomSeattle$64K
- John MerrittSeattle$15K
- Sirisak ChanprasertSeattle$60
- Katrina DippleSeattle$5
- Michael RaffTacoma$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.